4.7 • 3.4K Ratings
🗓️ 28 February 2024
⏱️ 164 minutes
🧾️ Download transcript
This episode is brought to you by Bioptimizers and Lumebox.
Dr. Thomas Seyfried's groundbreaking research approaches cancer as a metabolic dysfunction and addresses its root cause. Although controversial, this approach has provided hope for practitioners and cancer patients. Today’s guests highlight the work of the Hippocrates Research Foundation, a non-profit that continues Dr. Seyfried’s work by helping cancer patients combat their disease through education on metabolic approaches to treatment.
Today on The Dhru Purohit Podcast, Dhru sits down with Den Stacey, who, after being diagnosed with Stage 4 cancer, embarked on a journey seeking guidance from the Hippocrates Research Foundation and ultimately became cancer-free. The HRF Team of Daniel Orrego, Dr. Gregory Howard, and Dr. Michelle Howard describe their research and approach to guiding those diagnosed with cancer, including implementing a protocol that starves the cancer and fuels the body.
In this episode, Dhru, Den, Daniel, and Drs. Gregory & Michelle Howard dive into (audio version / Apple Subscriber version):
Also mentioned in this episode:
Go to bioptimizers.com/dhru now and enter promo code DHRU10 to get 10% off any order and up to 2 travel-size bottles of Magnesium Breakthrough for a limited time.
Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 50% off! Go to thelumebox.com/dhru and get your Red Light device.
Hosted on Acast. See acast.com/privacy for more information.
Click on a timestamp to play from that location
0:00.0 | Hi everyone, Drew Prote here. On today's episode, we're walking you through cancer as a metabolic disease and a step-by-step protocol that one individual followed when it comes to the research and work of Dr Thomas Safreed. |
0:15.4 | Now a little quick background. |
0:17.2 | Dr Thomas Seafreed is one of the world's leading cancer researchers. |
0:21.5 | In fact, he's been on this podcast before and his episode has |
0:25.8 | over 1.2 million views. Now back in 2012 Dr. Seifred published a groundbreaking book titled, |
0:35.5 | Cancer as a metabolic disease on the origin, management and prevention of cancer. In that book, Dr. Safreed lays out his groundbreaking research |
0:47.0 | and breaks down his press pulse protocol, |
0:50.0 | which is a novel therapeutic strategy for the management of cancer. |
0:55.0 | Now that protocol includes a whole host of things including metabolic therapies |
1:01.0 | like caloric restriction, fasting, a ketogenic diet, and a few additional |
1:06.8 | therapeutics including hyperbaric oxygen and drug management. |
1:11.2 | And this protocol has been proven in Dr. |
1:13.9 | Cefree's research in mice to slow down an even reverse tumor growth. |
1:19.7 | But here's the thing, if you interview Dr. Thomas Cefreed, like like I did it's hard to get a true sense of |
1:25.8 | everything involved in the protocol for human beings and that's because the protocol |
1:30.6 | is super in-, incredibly technical, and also in the category of highly experimental. |
1:39.2 | And the last thing Dr. Seifred wants to do is to give anyone a false sense of hope by only covering little bits and |
1:46.8 | pieces of his protocol. |
1:48.4 | But today we have an incredible guest on the podcast. |
1:51.4 | His name is Den Stacy and he's walking us through his step by step |
1:56.1 | end of one experience following Dr Safreed's recommendations and protocol |
2:01.3 | through the support of his team at the Hippocrates Research Foundation. |
... |
Transcript will be available on the free plan in -389 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Dhru Purohit, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Dhru Purohit and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.